EMAIL THIS PAGE TO A FRIEND

Molecular pharmaceutics

Tracking targeted bimodal nanovaccines: immune responses and routing in cells, tissue, and whole organism.


PMID 25290882

Abstract

Dendritic cells (DCs) are the most potent antigen-presenting cells (APCs), involved in the induction of immunity and currently exploited for antitumor immunotherapies. An optimized noninvasive imaging modality capable of determining and quantifying DC-targeted nanoparticle (NP) trajectories could provide valuable information regarding therapeutic vaccine outcome. Here, targeted poly(d,l-lactide-co-glycolide) nanoparticles (PLGA NPs) recognizing DC receptors were equipped with superparamagnetic iron oxide particles (SPIO) or gold nanoparticles with fluorescently labeled antigen. The fluorescent label allowed for rapid analysis and quantification of DC-specific uptake of targeted PLGA NPs in comparison to uptake by other cells. Transmission electron microscopy (TEM) showed that a fraction of the encapsulated antigen reached the lysosomal compartment of DCs, where SPIO and gold were already partially released. However, part of the PLGA NPs localized within the cytoplasm, as confirmed by confocal microscopy. DCs targeted with NPs carrying SPIO or fluorescent antigen were detected within lymph nodes as early as 1 h after injection by magnetic resonance imaging (MRI). Despite the fact that targeting did not markedly affect PLGA NP biodistribution on organism and tissue level, it increased delivery of NPs to DCs residing in peripheral lymph nodes and resulted in enhanced T cell proliferation. In conclusion, two imaging agents within a single carrier allows tracking of targeted PLGA NPs at the subcellular, cellular, and organismal levels, thereby facilitating the rational design of in vivo targeted vaccination strategies.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

P3415
3-(2-Pyridyldithio)propionic acid N-hydroxysuccinimide ester, ≥95%, powder
C12H12N2O4S2
09859
Ammonium hydroxide solution, BioUltra, ~1 M NH3 in H2O (T)
H5NO
M6020
D-(+)-Mannose, powder, BioReagent, suitable for cell culture
C6H12O6
M2069
D-(+)-Mannose, from wood, ≥99%
C6H12O6
M8574
D-(+)-Mannose, synthetic, ≥99%
C6H12O6
63579
D-(+)-Mannose, BioUltra, ≥99.5% (sum of enantiomers, HPLC)
C6H12O6
63580
D-(+)-Mannose, for microbiology, ≥99%
C6H12O6
63582
D-(+)-Mannose, for microbiology, ≥99.0% (sum of enantiomers, HPLC)
C6H12O6
44208
L-Lysine hydrochloride solution, 100 mM amino acid in 0.1 M HCl, analytical standard
C6H14N2O2 · HCl
PHR1101
L-Lysine monohydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
C6H14N2O2 · HCl
67448
L-Lysine monohydrochloride, certified reference material, TraceCERT®
C6H14N2O2 · HCl
L0900000
Lysine hydrochloride, European Pharmacopoeia (EP) Reference Standard
C6H14N2O2 · HCl
128910
N,O-Bis(trimethylsilyl)acetamide, synthesis grade, ≥95%
C8H21NOSi2
15269
N,O-Bis(trimethylsilyl)acetamide, for GC derivatization, LiChropur, ≥98.5% (GC)
C8H21NOSi2
394831
N,O-Bis(trimethylsilyl)acetamide, for GC derivatization
C8H21NOSi2
56480
N-Hydroxysuccinimide, purum, ≥97.0% (T)
C4H5NO3
W281506
Oleic acid, natural, FCC
C18H34O2
75090
Oleic acid, analytical standard
C18H34O2
O1383
Oleic acid, suitable for cell culture, BioReagent
C18H34O2
27728
Oleic acid, meets analytical specification of Ph, Eur., 65.0-88.0% (GC)
C18H34O2
Y0001479
Oleic acid, European Pharmacopoeia (EP) Reference Standard
C18H34O2
05508
Oleic acid, Selectophore, ≥99.0%
C18H34O2